On March 8, 2022 Merus N.V. (Nasdaq: MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), reported the publication of the abstract highlighting the mechanism of action of MCLA-129 on the American Association for Cancer Research (AACR) (Free AACR Whitepaper) website (Press release, Merus, MAR 8, 2022, View Source [SID1234609803]). MCLA-129, is a Biclonics, which binds to EGFR and c-MET; EGFR is an important oncogenic driver in many cancers, and upregulation of c-MET signaling has been associated with resistance to EGFR inhibition. The poster will be on display at the AACR (Free AACR Whitepaper) Annual Meeting 2022 in New Orleans, Louisiana on Sunday, April 10, 2022 and available on the e-poster website beginning on Friday, April 8 at 1:00 p.m. ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Title: Mechanism of action of MCLA-129, a bispecific antibody that targets EGFR and c-MET and impairs growth of EGFR exon 20 insertion mutant non-small cell lung cancer
Session Date and Time: Sunday, April 10, 2022 1:30 p.m. – 5:00 p.m. CT
Session Category: Experimental and Molecular Therapeutics
Session Title: Biological Therapeutic Agents and Novel Drugs
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 22
Abstract Number: 336
The full poster will also be available on our website beginning on Friday, April 8 at 1:00 p.m. ET.
MCLA-129 is currently enrolling patients in a phase 1/2, open-label clinical trial consisting of dose escalation followed by a planned dose expansion. Primary objectives of phase 1 are to determine the maximum tolerated dose and/or the recommended phase 2 dose, and the objectives of phase 2 are to evaluate safety, tolerability and potential clinical activity in patients with advanced solid tumors. MCLA-129 is subject to a collaboration and license agreement with Betta Pharmaceuticals Co. Ltd. (Betta), which permits Betta to develop MCLA-129 exclusively in China, while Merus retains global rights outside of China. In October 2021, Betta announced that the first patient was dosed in a phase 1/2 trial in China sponsored by Betta, of MCLA-129 in patients with advanced solid tumors. Merus plans to provide a clinical update in the second half of 2022.